← Back to Home

Seeking an Opportunity to Intervene in Childhood Vision Loss: Opus Begins Human Trial of RDH12 Gene Therapy

The first participant has been dosed with OPGx-RDH12, which aims to deliver a functional gene into retinal photoreceptor cells. This step brings the treatment concept into human testing, but no patient data are yet available to determine whether it can safely preserve vision.

By SURL BioNews

For inherited retinal diseases in which vision loss begins in childhood, a central question in treatment research is whether intervention is possible before function deteriorates further. Opus Genetics announced on November 19 that the first participant had been dosed in a Phase 1/2 clinical trial of OPGx-RDH12, its gene therapy being developed for RDH12-associated Leber congenital amaurosis (RDH12-LCA), bringing it into human testing.

According to the company announcement and the same press release published on BioSpace, this development follows the U.S. Food and Drug Administration (FDA) clearance of its investigational new drug application in October of this year. This allows the study to begin; it does not mean the therapy has been approved for marketing. The announcement names Kenneth Fan of Retina Consultants of Texas in Houston as the principal investigator.

RDH12-LCA causes progressive vision loss beginning in early childhood. OPGx-RDH12 is designed to use an adeno-associated virus (AAV) vector to deliver a functional copy of the RDH12 gene into retinal photoreceptor cells, with the hope of compensating for the functional deficiency caused by the genetic defect and thereby preserving retinal function and vision. This is the goal of the treatment design and cannot yet be regarded as an effect demonstrated in patients.

The trial will assess safety and tolerability and track retinal structure and visual function using exploratory measures. Dosing the first participant is therefore a milestone in the study's progress; the announcement disclosed no patient efficacy results and provided no follow-up data sufficient to assess safety in humans. Whether vision can be maintained and how long any effect might last will require further observation.

Resources supporting the research also come from patient advocacy groups. The Global RDH12 Alliance, comprising the U.S.-based RDH12 Fund for Sight and the UK-based Eyes on the Future, has committed up to US$1.6 million toward development. According to the announcement, eligible development expenses will be reimbursed as work is completed, subject to agreed obligations and milestones; the funding has not all been received.

For patients and their families, the human trial offers a treatment pathway that is beginning to undergo practical testing. The next substantive evidence will come from safety follow-up after dosing and whether sustained changes emerge in retinal and visual function. Until those data become available, preserving vision remains a goal the research hopes to achieve.

References

  1. Opus Genetics
  2. BioSpace (Opus Genetics press release)